cp wire

CP Wire Articles

Argenx To Raise $300 million in U.S. public offering
  • argynx has 8 drugs in development
  • Partners include Abbvie, LEO Pharma, and Staten Biotech

argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company... read more

Wed, 09/19/18 - 09:32 am
Canada Approves Cabometyx for Adults with Previously Treated Advanced Renal Cell Carcinoma
  • Cabometyx has orphan drug status in the US
  • Takeda has rights to all indications for Cabometyx in Japan


Exelixis, Inc.  (NASDAQ:EXEL) announced on 9/19/18 that its... read more

Wed, 09/19/18 - 09:16 am
AmpliPhi Recieves Positive FDA Feedback for its Bacteriophage Candidate AB-PA01 Development Plans Targeting Pseudomonas Aeruginosa Infections
  • Company received positive written response from FDA regarding development plans
  • Resistant P. aeruginosa is designated as ‘Priority 1: Critical’ pathogen by the World Health... read more
Tue, 09/18/18 - 09:07 am
Ph II Trials of DPX-Survivac in Combination with Ketruda Yield Positive Results in Patients With Diffuse Large B-cell Lymphoma
  • Two of the first four evaluable participants showed tumor regressions at the first on-treatment CT scan
  • DPX-Survivac has received fast-track status from FDA
  • It also has... read more
Tue, 09/18/18 - 08:45 am
Bacteriophage Company Reports Success With Expanded Access Program For Resistant Infections



AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections... read more

Mon, 09/17/18 - 09:08 am

Pages